The UCL Institute of Healthy Ageing and the Max Planck Institute for Biology of Ageing demonstrate that combined administration of rapamycin and trametinib extends mouse lifespan by approximately 30% through synergistic modulation of the Ras/Insulin/TOR and ERK signalling networks, also reducing chronic inflammation and tumour onset.

Key points

• Combined rapamycin and trametinib extends mouse lifespan by ~30%.
• Combination therapy reduces chronic inflammation and delays tumour onset in aged mice.
• Transcriptomic analysis reveals unique gene expression changes with combined treatment versus monotherapy.

Why it matters: This synergistic geroprotector combination paradigm offers a powerful approach to delay ageing, reduce inflammation, and prevent cancer more effectively than single agents.